Trial ID or NCT#

NCT02319005

Status

RECRUITING

Purpose

The purpose of this study is to evaluate the safety and efficacy of Revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy.

Investigator(s)

Jared Gollub, MD

Contact us to find out if this trial is right for you.

CONTACT

Alnylam Pharmaceuticals